Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Cerilliant
US Army
UBS
Dow
Cipla
Fish and Richardson
Fuji
Citi

Generated: October 23, 2017

DrugPatentWatch Database Preview

Genentech Company Profile

« Back to Dashboard

What is the competitive landscape for GENENTECH, and when can generic versions of GENENTECH drugs launch?

GENENTECH has nine approved drugs.

There are twenty-four US patents protecting GENENTECH drugs.

There are three hundred and one patent family members on GENENTECH drugs in forty-four countries and nineteen supplementary protection certificates in eleven countries.

Summary for Applicant: Genentech

International Patents:301
US Patents:24
Tradenames:10
Ingredients:6
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech
NUTROPIN AQ PEN
somatropin recombinant
INJECTABLE;INJECTION020522-002Apr 22, 2002RXYesYes► Subscribe► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Genentech
NUTROPIN AQ
somatropin recombinant
INJECTABLE;INJECTION020522-001Dec 29, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Genentech

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-003Dec 22, 1999► Subscribe► Subscribe
Genentech
PROTROPIN
somatrem
INJECTABLE;INJECTION019107-001Oct 17, 1985► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-003Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-001Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-003Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-002Dec 22, 1999► Subscribe► Subscribe
Genentech
NUTROPIN
somatropin recombinant
INJECTABLE;INJECTION020168-002Nov 17, 1993► Subscribe► Subscribe
Genentech
NUTROPIN DEPOT
somatropin recombinant
INJECTABLE;INJECTION021075-003Dec 22, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Genentech

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,166,523► Subscribe
7,867,516Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient► Subscribe
9,321,761Pyridyl inhibitors of hedgehog signalling► Subscribe
9,017,722Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone► Subscribe
7,915,250Azetidines as MEK inhibitors for the treatment of proliferative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Genentech Drugs

Country Document Number Estimated Expiration
African Regional IP Organization (ARIPO)200804390► Subscribe
South Korea20150090263► Subscribe
South Korea20120139846► Subscribe
Hong Kong1145138► Subscribe
New Zealand589385► Subscribe
Denmark2343070► Subscribe
Cyprus1111699► Subscribe
Canada2762013► Subscribe
European Patent Office3143997► Subscribe
Slovenia1940364► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Genentech Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90057-6Sweden► SubscribePRODUCT NAME: VISMODEGIB OCH SOLVAT DAERAV; NAT. REG. NO/DATE: EU/1/13/848 20130712; FIRST REG.: CH IKS-NR 62497 20130530
278Luxembourg► SubscribePRODUCT NAME: VISMODEGIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(ERIVEDGE)
0 12-2013Slovakia► SubscribePRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: EU/1/13/848/001 20130712
2013 00050Denmark► SubscribePRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
0160012 00193Estonia► SubscribePRODUCT NAME: KOBIMETINIIB;REG NO/DATE: EU/1/15/1048 24.11.2015
078Luxembourg► SubscribePRODUCT NAME: COBIMETINIB, EVENTUELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE, Y COMPRIS LES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER HEMIFUMARATE DE COBIMETINIB; FIRST REGISTRATION DATE: 20151124
2013 00050Denmark► SubscribePRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
1789390/01Switzerland► SubscribePRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: SWISSMEDIC 62497 30.05.2013
2013024Lithuania► SubscribePRODUCT NAME: VISMODEGIBUM; NAT. REGISTRATION NO/DATE: SWISS 62497 01 20130530; FIRST REGISTRATION: EU/1/13/848 20130712
0809Netherlands► SubscribePRODUCT NAME: COBIMETINIBI, DESGEWENST FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN DAARVAN, IN HET BIJZONDER COBIMETINIB HEMIFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1048 20151124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
Cerilliant
Fuji
Medtronic
Argus Health
Baxter
McKinsey
Express Scripts
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot